Aurinia Pharmaceuticals (AUPH) PT Lowered to $22 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts AUPH Hot Sheet
Price: $16.14 -3.06%
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
RBC Capital analyst Douglas Miehm lowered the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $22.00 (from $27.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Aurinia Pharmaceuticals (AUPH) PT Raised to $18 at RBC Capital
- CRH plc (CRH) PT Raised to $120 at Truist Securities
- Marriott International (MAR) PT Raised to $402 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
